A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies (NCT07024784)
A Phase 1b Dose Escalation and Expansion Study of IMGN151 as Monotherapy and in Combination With Other Anti-Cancer Therapies in Subjects With Gynecologic Cancers
🩺 Plain-English Summary (8th-Grade Level)
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety and tolerability of IMGN151 when given as monotherapy and in combination with other anti-cancer therapies in adult participants with gynecologic cancers. IMGN151 is an investigational drug being developed for the treatment of gynecologic cancers. Participants are placed in 1 of 4 groups, called treatment arms. Each group receives a different treatment. Around 377 participants with gynecologic cancers will be enrolled in the study at approximately 50 sites worldwide. Participants will receive intravenous infusions of IMGN151 as monotherapy or in combination with anti-cancer therapies according to their assigned study arm. In Arm A, participants will receive IMGN151 in combination with carboplatin on Day 1 of each cycle. In Arm B, participants will receive IMGN151 in combination with olaparib, twice a day (BID) on Day 1 of each cycle. In Arm C, participants will receive IMGN151 in combination with bevacizumab on Day 1 of each cycle. In Arm D, participants will receive IMGN151 as monotherapy on Day 1 of each cycle. In Arm E, participants will receive IMGN151 as monotherapy on Day 1 of each cycle. In Arm F, participants will receive IMGN151 as monotherapy on Day 1 of each cycle. The total study duration will be approximately 3 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.
Who can join: Review the eligibility criteria below.
Location: Holy Name Medical Center /ID# 279017 — Teaneck, New Jersey
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (16 Sites)
- Holy Name Medical Center /ID# 279017 — Teaneck, New Jersey
- University of Cincinnati Medical Center. /ID# 278925 — Cincinnati, Ohio
- OU Health - Stephenson Cancer Center /ID# 277656 — Oklahoma City, Oklahoma
- Providence Portland Medical Center /ID# 277727 — Portland, Oregon
- Women & Infants Hospital /ID# 277930 — Providence, Rhode Island
- SCRI Oncology Partners /ID# 279733 — Nashville, Tennessee
- Texas Oncology-Austin North /ID# 279958 — Austin, Texas
- Next Virginia /ID# 279684 — Fairfax, Virginia
- Rabin Medical Center /ID# 279142 — Petah Tikva, Central District
- The Chaim Sheba Medical Center /ID# 275997 — Ramat Gan, Tel Aviv
- Tel Aviv Sourasky Medical Center /ID# 275852 — Tel Aviv, Tel Aviv
- Rambam Health Care Campus- Haifa /ID# 276004 — Haifa,
- Shaare Zedek Medical Center /ID# 275854 — Jerusalem,
- Hyogo Cancer Center /ID# 276940 — Akashi-shi, Hyōgo
- National Cancer Center Hospital /ID# 276715 — Chuo-Ku, Tokyo
- The Cancer Institute Hospital Of JFCR /ID# 276711 — Koto-ku, Tokyo
📞 Contact the Study Coordinator
Phone: (844) 663-3742
Email: abbvieclinicaltrials@abbvie.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Gynecologic Cancers
- Pelvic Health Rehabilitation After Breast and Gynecologic Cancer — Edmonton, Alberta
- Communication About Sexual Health in Gynecologic Cancer — Philadelphia, Pennsylvania
- A Prospective Study of a Lifestyle Medicine Survivorship Program for Patients With Gynecologic Cancer — Orlando, Florida
- Virtual Mindful After Cancer (MAC) Intervention to Promote Sexual Health for Breast and Gynecologic Cancer Survivors — Corvallis, Oregon
- eSense-Cancer: Adapting an Online Intervention for Sexual Health Concerns to Gynecologic Cancer — Vancouver, British Columbia
Explore by condition: All Gynecologic Cancers clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.